Le Lézard
Classified in: Business
Subject: ATY

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lipocine, Armstrong Flooring, Wanda Sports Group, and Canopy Growth and Encourages Investors to Contact the Firm


NEW YORK, Dec. 11, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Lipocine, Inc. (NASDAQ: LPCN), Armstrong Flooring, Inc (NYSE: AFI), Wanda Sports Group Company Limited (NASDAQ: WSG), and Canopy Growth Corporation (NYSE: CGC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

(PRNewsfoto/Bragar Eagel & Squire, P.C.)

Lipocine, Inc. (NASDAQ: LPCN)

Class Period: March 27, 2019 to November 8, 2019

Lead Plaintiff Deadline: January 14, 2020

Lipocine's lead product candidate is TLANDO (LPCN 1021), an oral testosterone replacement therapy.  The Company has previously submitted New Drug Applications ("NDA") for TLANDO twice and, both times, received Complete Response Letters ("CRL") from the U.S. Food and Drug Administration ("FDA") rejecting the NDAs.  The Company received the first CRL in June 2016 and the second in May 2018.

On March 27, 2019, Lipocine issued a press release announcing new topline results from a study evaluating TLANDO's effects on blood pressure (one issue cited by the FDA in a prior CRL rejecting TLANDO's NDA), as well as the Company's intention to refile the NDA for TLANDO in the second quarter of 2019.

On November 11, 2019, Lipocine issued a press release announcing receipt of a CRL from the FDA regarding its NDA for TLANDO.  In the press release, Lipocine advised investors that the FDA had again rejected the NDA for TLANDO?this time because an efficacy trial had not met three of its secondary endpoints.

On this news, Lipocine's stock price fell $1.93 per share, or 70.7%, to close at $0.80 per share on November 11, 2019.

The Complaint, filed on November 14, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the results from Lipocine's clinical studies of TLANDO were insufficient to demonstrate the drug's efficacy; (ii) accordingly, Lipocine's third NDA for TLANDO was highly likely to be found deficient by the FDA; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

For more information on the Lipocine class action go to: https://bespc.com/lpcn

Armstrong Flooring, Inc. (NYSE: AFI)

Class Period: March 6, 2018 to November 4, 2019

Lead Plaintiff Deadline: January 14, 2020

On May 3, 2019, Armstrong Flooring's Chief Executive Officer abruptly resigned.

On this news, the Company's stock price fell $1.75, nearly 12%, to close at $13.14 per share on May 3, 2019.

Then, on November 5, 2019, Armstrong Flooring reported $165.6 million net sales for third quarter 2019, a nearly 21% decline year-over-year, and a net loss of $31.4 million. The Company also cut its full year 2019 guidance for adjusted EBITDA to a range of $20 million to $25 million, from prior guidance range of $46 million to $54 million, citing "larger distributor movements on inventory" than anticipated.

On this news, the Company's stock price fell $2.90 per share, or nearly 44%, to close at $3.70 per share on November 5, 2019.

The complaint, filed on November 15, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company had engaged in channel stuffing to artificially boost sales; (2) that the Company's internal control over inventory levels was not effective; and (3) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

For more information on the Armstrong Flooring class action go to: https://bespc.com/afi

Wanda Sports Group Company Limited (NASDAQ: WSG)

Class Period: Securities purchased pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with Wanda Sports' July 26, 2019 initial public offering ("IPO").

Lead Plaintiff Deadline: January 17, 2020

In July 2019, Wanda Sports held its IPO, issuing approximately 23.8 million American Depository Shares ("ADSs") at $8.00 per share, pursuant to the Registration Statement. Wanda Sports' shares have lost nearly 60% of their value, closing at $2.78 on November 18, 2019.

The complaint, filed on November 18, 2019, alleges that defendants made statements that were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company's business, operations and prospects: (1) the lack of major sporting events for its DPSS and Spectator Sports segments for its second quarter of 2019, ending before the IPO, would negatively impact revenue for the second quarter of 2019; (2) Wanda Sports had suffered a year-over-year decrease in revenue in its second quarter ended June 30, 2019 and would for its fiscal year 2019, primarily related to lower reimbursement revenues accounted for in its DPSS segment and lack of Spectator Sport segment offsets; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

For more information on the Wanda Sports class action go to: https://bespc.com/wsg

Canopy Growth Corporation (NYSE: CGC)

Class Period: Securities purchased between June 21, 2019 and November 13, 2019 on the New York Stock Exchange.

Lead Plaintiff Deadline: January 20, 2020

On November 14, 2019, before the market opened, the Company issued a press release announcing their earnings for the second quarter of fiscal year 2020, posting a larger-than-expected loss for the quarter. The Company announced it would be modifying its retail pricing architecture and taking a CA$32.7 million restructuring charge.

On this news, shares of Canopy fell $2.36 per share or nearly 14.4% to close at $15.84 per share on November 14, 2019, damaging investors.

The complaint, filed on November 21, 2019, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing weak demand for its softgel and oil products; (2) as a result, the Company would be forced to take a CA$32.7 million restructuring charge due to poor sales, excessive returns, and excess inventory; and (3) due to the foregoing, defendants' statements about Canopy's receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

For more information on the Canopy Growth class action go to: https://bespc.com/cgc

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected] 
www.bespc.com

SOURCE Bragar Eagel & Squire, P.C.


These press releases may also interest you

at 05:00
TAL Education Group ("TAL" or the "Company") , a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the fourth quarter and fiscal year 2024 ended February 29, 2024, before the market...

at 04:25
Ademi LLP is investigating Doma  for possible breaches of fiduciary duty and other violations of law in its transaction with Title Resources Group. ...

at 04:00
U Power Limited (the "Company" or "U Power"), a vehicle sourcing services provider with a vision to becoming a comprehensive EV battery power solution provider in China, today announced that the Company held an extraordinary general meeting of...

at 04:00
Tonight on BBC1, REMY founder Abeer Iqbal, entered the Den, and despite intense grilling and no investment, left with a six-figure job offer from Peter Jones. ...

at 04:00
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against The Chemours Company ("Chemours" or "the Company") and certain of its officers....

at 03:57
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of those who held the common stock of Northern Genesis Acquisition Corp. n/k/a The Lion Electric Company as of the record date of March...



News published on and distributed by: